Search
Triamterene
go.drugbank.com/drugs/DB00384ApprovedIt works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.
Mixtures: Nu-triazide Tab 50 Mg/25 mgTedizolid phosphate
go.drugbank.com/drugs/DB09042Approved[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTestosterone propionate
go.drugbank.com/drugs/DB01420ApprovedInvestigationalVet approvedWithdrawn[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. … Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigational[L34650] Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). … hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.
Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is … not available in North America [L1543].
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022] … Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256408] By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity
Islatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently … [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency.
Zuclopenthixol
go.drugbank.com/drugs/DB01624ApprovedInvestigationalIt is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCorifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalElonva is available only by prescription [L2270]. In July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug. … This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].